Integrated Management Of Chronic Diseases In Multiunit Shared Surgery

Author(s)

De Fina Mariarosanna , Adele Emanuela De Francesco , Mariacristina Zito , Stefania Esposito , Cristina Monopoli , Giovambattista De Sarro ,

Download Full PDF Pages: 143-148 | Views: 616 | Downloads: 190 | DOI: 10.5281/zenodo.4971429

Volume 9 - July 2020 (07)

Abstract

Chronic diseases have a significant impact on health and socio-health care, in terms of premature death, chronicity or disability. Numerous scientific evidences have shown that some pathologies affecting the immune system depend on common pathogenetic mechanisms in which the number of patients presenting with Rheumatological, Dermatological or Gastroenterological comorbidities ranges between 25% to 40%. The research was conducted through an expert panel, which share skills and knowledge about the management of IMiDs pathologies. The panellists suggested a new planning of the treatment path. They recommended the presence of the hospital pharmacist, who guarantees the safety of treatments. The study highlights how the multidisciplinary approach in the hospital setting is able to increase the effectiveness of treatments and at the same time reduce indirect costs

Keywords

clinical governance, multidisciplinarity, effectiveness, IMiDs.

References

                   i.            Anrioli Stagno R, Bertazzi I, Boccadoro M, Cannizzaro G, Cardone R, Carnevale G, et al. Il farmacista di dipartimento quale strumento per la prevenzione degli errori in terapia e l’implementazione delle politiche di governo clinico in ambito oncologico. Min Sal. 2011.

      ii.            Boyd C, Fortin M, Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Heath Reviews. 2010. 32:451-471.

    iii.            Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012. 380:37-43.

     iv.            Brescia V, Indelicato A, Chmet F, Maglio P, Muraca L, Mazzei A, Guzzo ML, Cardona R, Bisogni K, Notarangelo M, De Fina M, Multidisciplinarity in the Treatment Process: An Essential Element in Clinical Governance, International Journal of Management Sciences and Business Research. 2019. 03:47-62

       v.            Borenstein DG, Hasset AL; Pisetsky DS, Pain management in rheumatology research, training, and practice. Clin Exp Rheum. 2017. 2-7.

     vi.            Capelli O, Quattrini B, Abate F, Casalgrandi B, Cacciapuoti I, Integrated care for chronic diseases- State of the art. Intech. 2016.

   vii.            Chen CC, Hsiao FY, Shen LJ, Wu CC, The cost-saving effect and prevention of medication errors by  clinical pharmacist intervention in a nephrology unit. Medicine. 2017. 96:34.

 viii.            Chinthammit C, Armstrong EP, Warholak TL, A cost-effectiveness evaluation of hospital discharge counseling by pharmacists. J Pharm Pract. 2012. 25:201-208.

     ix.            Dalton K, Byne S, Role of pharmacist in reducing healthcare costs: current insights. Int Pharm Res and Pract. 2017. 6:37-46.

       x.            De Rijdt T, Willems L, Simoens S. Economic effect of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm. 2008. 65:1161-1172.

     xi.            Hawes EM, Misita C, Burkhart JI, et al. Prescribing pharmacists in the ambulatory care setting: experience at the University of North Carolina Medical Center. Am J Health Syst Pharm. 2016. 73:1425-1433.

   xii.            Jacknin G, Nakamura T, Smally A, Ratzan R. Using pharmacists to optimize patient outcomes and costs in the ED. Am J Emerg Med. 2014. 32: 673-677.

 xiii.            Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006.166 (9):955-964.

 xiv.            Kopp BJ, Mrsan M, Erstad BL, Duby JJ, Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007. 64: 2483-2487.

   xv.            Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA, Pharmacists on rounding teams reduce preventivable adverse drug events in hospital general medicine units. Arch Intern Med. 2003. 163:2014-2018.

 xvi.            Lada P, Delgado G Jr. Documentation of pharmacists’ interventions in an emergency department and associated cost avoidance. Am J Health Syst Pharm. 2007. 64:63-68.

xvii.            Lombardi N, Wei L, Ghaleb M, Pasut E, Leschiutta S, Rossi P, Troncon MG, Evaluation of the implementation of a clinical pharmacy service on an  acute internal medicine ward in Italy. BMC Haelth Serv Res. 2018. 18:259.

xviii.            Merengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, Meinow B, Fratiglioni L, Aging with multimorbidity: a systematic review of the literature. Ageing Research Reviews. 2011. 10: 430-439.

 xix.            McMullin ST, Hennenfent JA, Ritchie DJ, et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999. 159: 2306-2309.

   xx.            Olson LM, Desai S, Soto ML, Namazifard S, Quelland AK, Erstad BL. Evaluation of pharmacist’ interventions at a university teaching hospital. Can J Hosp Pharm. 2005. 58: 20-25.

 xxi.            Polidori P, Cifani C, Polidori C, Roles of hospital and territorial pharmacists within the italian national healthcare service. CJHP. 2017. 70: 309-315.

xxii.            Pronovost P, Weast B, Schwarz M, Wyskiel RM, Prow D, Milanovich SN, Berenholtz S, Dorman T, Lipsett P. Medication reconciliation: a practical tool to reduce the risk of medication errors. J Crit Care. 2003 Dec;18(4):201-5.

xxiii.            Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, et al., Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission. A randomized clinical trial. JAMA Int Med. 2018. 178: 375-382.

xxiv.            Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003. 23:113-132.

xxv.            Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA. New treatments for inflammatory rheumatic disease. Immunol Res. 2014. 60:277-88.

xxvi.            Yasunaga D, Tasaka Y, Murakami S, Tanaka A, Tanaka M, Araki H. Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japa. J. Pharm Policy Pract. 2016. 10:2.

xxvii.            Wickens HJ, Farrell S, Ashiru-Oredope DA, et al. The increasing role of pharmacists in antimicrobial stewardship in English hospitals. J Antimicrob Chemother. 2013. 68: 2675-2681.

xxviii.            Vare P, Nikiphorou E, Hannonen P, Sokka T, Delivering a one-stop, integrated, and patient-centered service for patient with rheumatic disease. SAGE Open Med. 2016.

De Fina Mariarosanna, Integrated Management Of Chronic Diseases In Multiunit Shared Surgery, International Journal of Management Sciences and Business Research 07(2020):143-148 DOI: 10.5281/zenodo.4971429